Trial Profile
Phase I COVID-19 vaccine study for treatment of corona virus infection
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 20 May 2020
At a glance
- Drugs MT 2766 (Primary)
- Indications Coronavirus infections; COVID 2019 infections
- Focus Adverse reactions
- Sponsors Medicago
- 14 May 2020 According to a Medicago media release, the company will submit an investigational new drug submission with the FDA in the United States to allow for the initiation of human clinical trials this summer.
- 18 Mar 2020 New trial record
- 12 Mar 2020 According to a Medicago media release, the company expects to discuss with the appropriate Health Agencies to initiate human trials of the vaccine by summer (July/August) 2020.
Most Recent Events
Trial Overview
Purpose
This study will investigate COVID-19 vaccine for treatment of corona virus infection.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| Coronavirus infections | treatment | - |
| COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
- Sex not stated
Trial Details
Organisations
- Sponsors Medicago
- Affiliations Medicago
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase I
- Location USA
- Focus Adverse reactions
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| MT 2766Primary Drug |
-
|
-
|
Coronavirus vaccine
Coronavirus vaccine
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 14 May 2020 | Other trial event | According to a Medicago media release, the company will submit an investigational new drug submission with the FDA in the United States to allow for the initiation of human clinical trials this summer. Updated 20 May 2020 |
| 18 Mar 2020 | New trial record | New trial record Updated 18 Mar 2020 |
| 12 Mar 2020 | Other trial event | According to a Medicago media release, the company expects to discuss with the appropriate Health Agencies to initiate human trials of the vaccine by summer (July/August) 2020. Updated 18 Mar 2020 |
References
-
Medicago. Medicago announces production of a viable vaccine candidate for COVID-19. Media-Rel 2020;.
Media Release -
Medicago. Medicago Announces Positive Results in Animal Trials for Its Vaccine Candidate Against COVID-19. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG